Guillo et al. found recently that ustekinumab [UST], a monoclonal antibody blocking the p40 subunit of the anti-interleukin [IL] 12/23, could be an effective option for the treatment of extraintestinal manifestations [EIMs] of Crohn's disease [CD], especially for der-matological and rheumatological manifestations. This antibody has been recently approved also in Italy for the use in refractory CD, and we would like to report the efficacy of UST in treating EIMs associated with CD and previously refractory to biologics. We reviewed our CD outpatients treated with UST, after failure of biologic therapies (including anti- tumour necrosis factor alpha [TNFalpha] antibodies and vedolizumab) for CD EIMs. All patients completing at least the induction treatment by December 31, 2019, were included. Men and women, at least 18 years of age and having an established diagnosis of CD according to standard endoscopic and/or radiological and/or histological criteria, were included.
展开▼
